C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients

<jats:sec><jats:title>Background</jats:title><jats:p>Serum C-reactive protein (CRP) is a biomarker of an acute inflammatory response and has been successfully used as a prognostic predictor for several malignancies. However, the clinicopathological significance of CRP levels in hepatocellular carcinoma (HCC) patients being treated with PD-1 inhibitors remains unclear.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Serum CRP levels were measured for a total of 101 HCC patients that had been treated with PD-1 inhibitors from July 2018 to November 2019. The clinicopathological data was retrospectively analyzed to identify any clinical implications between CRP levels and responses to PD-1 inhibitors and patients’ progression-free survival (PFS).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>The median PFS was 8.87 months in the CRP-low subgroup and 3.67 months in the CRP-high subgroup (<jats:italic>P =</jats:italic> 0.009). Univariate and multivariate Cox regression analysis demonstrated that both serum CRP and AFP levels were independent risk factors for the PFS of HCC patients treated with PD-1 inhibitors (<jats:italic>P</jats:italic> &lt; 0.05). Moreover, Cox regression analysis after Propensity Score Matching showed the similar results. A prognostic model combining CRP and AFP levels could significantly stratify HCC patients receiving PD-1 inhibitors into low-, intermediate-, and high-risk subgroups (<jats:italic>P</jats:italic> &lt; 0.001). Patients in the risk subgroups reported similar overall response rates (<jats:italic>P =</jats:italic> 0.625) and significantly different disease control rates (low- vs. intermediate- vs. high-risk groups: 81.6% vs. 65.1% vs. 35%, respectively, <jats:italic>P =</jats:italic> 0.002).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The results of this study support the association between high serum CRP levels with the response and PFS for HCC patients receiving PD-1 inhibitors. Furthermore, the levels of both CRP and AFP in an HCC patient before treatment initiation show great potential for determining the efficacy of PD-1 inhibitors.</jats:p></jats:sec>